Starpharma Holdings Limited · ASX:SPL
Starpharma — Investor Presentation (October 2026)
17 slides from Starpharma's investor presentation, Oct 21, 2026
Slide 1: ASX Announcement: Starpharma Investor Presentation – Petalion Webinar
ASX Announcement Starpharma Investor Presentation – Petalion Webinar For personal use only Melbourne, Australia; 21 October 2026: Starpharma (ASX: SPL, US OTC: SPHRY), an innovative biotechnology company advancing dendrimer technology from the lab to the patient, provides the investor presentation d
Slide 2: Starpharma secures majority ownership of Petalion
rsonal use only Starpharma secures majority ownership of Petalion LEADING THE NEXT STAGE OF THE FAP-TARGETED DEP® ONCOLOGY PROGRAM I N V E STO R P R E S E N TAT I O N 21 OCTOBER 2026
Slide 3: Disclaimer and Forward-Looking Statements
Disclaimer and Forward-Looking Statements rsonal use only This presentation contains forward-looking statements that involve risks and uncertainties. Although we believe that the expectations reflected in the forward-looking statements are reasonable at this time, Starpharma can give no assurance th
Slide 4: Key Highlights: Petalion Update
Key Highlights: Petalion Update Starpharma will lead the FAP-targeted DEP® oncology program, with Medicxi remaining a strategic partner and substantial shareholder rsonal use only MAJORITY OWNERSHIP DEFINED INVESTMENT NEXT DEVELOPMENT PHASE UP TO AUD Lead candidate 66% $5.0m selection up from 22.5%
Slide 5: Starpharma's Mission and Purpose
Starpharma’s Mission and Purpose Redefining cancer treatment with dendrimer science rsonal use only Our mission Help patients with significant illnesses, such as cancer, achieve improved health outcomes and quality of life through the application of our unique dendrimer technology. I N V E S T O R P
Slide 6: Two Complementary DEP Approaches to Drive Shareholder Value
Two Complementary DEP® Approaches to Drive Shareholder Value Building value through proprietary assets and strategic partnerships rsonal use only OWN AND ADVANCE Build differentiated DEP® oncology assets in selected high Proprietary value therapeutic areas. assets VALUE: asset ownership • partnering
Slide 7: Disciplined Selection of Proprietary DEP Assets
Disciplined Selection of Proprietary DEP® Assets Focusing capital where patient need, platform advantage and value potential align rsonal use only HIGH UNMET NEED CLEAR DEP® ADVANTAGE ATTRACTIVE VALUE POTENTIAL Meaningful patient need and scope A defined role for DEP® in improving Strong scientific
Slide 8: Evolving Asset Pipeline
Evolving Asset Pipeline Strategic focus on targeted therapies and partnerships in oncology to drive shareholder value rsonal use only Target Pre- Product Phase I Phase II Phase III Status Partner Pipeline Indication clinical Combined $1B+ deal value Targeted Therapies DEP® HER2-Lutetium 3L treatment
Slide 9: Petalion Joint Venture
Petalion Joint Venture Petalion’s evolution reflects a typical asset-centric investment model rsonal use only Medicxi Partner Pipeline European VC with 20+ years of experience in drug discovery, developing therapeutics for unmet medical needs, partnering, investment & asset sale Combined $1B+ deal v
Slide 10: Greater Ownership and Continued Strategic Support
Greater Ownership and Continued Strategic Support The revised structure combines majority ownership with direct program leadership Established in 2024, Petalion focuses on one FAP-targeted oncology program using Starpharma’s proprietary DEP® dendrimer platform. Starpharma has increased its ownership
Slide 11: FAP and DEP: Scientific Rationale and Strategic Value
FAP and DEP®: Scientific Rationale and Strategic Value Expanding potential across solid tumours rsonal use only FAP target DEP® delivery Strategic value Fibroblast activation protein (FAP) is highly Petalion’s FAP-targeted conjugate uses A high-value, externally validated target extends expressed on
Slide 12: Where Petalion Now Sits Within Our Portfolio
Where Petalion Now Sits Within Our Portfolio Aligns with strategic focus on targeted therapies and partnerships in oncology to drive shareholder value rsonal use only Target Pre- Product Phase I Phase II Phase III Status Partner Pipeline Indication clinical Combined $1B+ deal value Targeted Therapie
Slide 13: One Platform. Two Complementary Routes To Value.
One Platform. Two Complementary Routes To Value. Advancing proprietary oncology assets while partnering DEP® innovation with leading life-science companies rsonal use only STRATEGIC PARTNERSHIPS PROPRIETARY ONCOLOGY ASSETS GENENTECH Oncology research collaboration RADIOPHARMACEUTICALS New and existi
Slide 14: Focused Execution for Partnerships and Asset Development
Focused Execution for Partnerships and Asset Development From clinical validation to global partnerships and advancing radiotheranostics rsonal use only Radiopharm Early-stage research Secured majority Theranostics option commenced on ownership in Radiopharm Early-stage Finalised period for exclusiv
Slide 15: Financial Summary
Financial Summary Well placed to execute our strategy rsonal use only A$11.0M A$30M A$44.5M Cash balance Net proceeds raised Pro forma cash at 11 August 2026 At 30 June 2026 Fully underwritten Entitlement Offer Includes R&D tax incentive receivable 11 August 2026 Funding priorities Cash runway A$17M
Slide 16: Focusing on Strategic Execution and Revenue Generation
Focusing on Strategic Execution and Revenue Generation Important catalysts we anticipate in the next 12-18 months rsonal use only 4Q CY26 1H CY27 2H CY27 DEP® HER2 Program DEP® HER2 Program DEP® HER2 Program • Final data readout from FIH study • Initial data readout from ~3-4 patients • Ethics appro
Slide 17: Thank you
rsonal use only Thank you Investor Relations Corporate Office Investor.Relations@Starpharma.com 4 – 6 Southampton Crescent www.Starpharma.com Abbotsford, Victoria 3067 Australia
Starpharma Holdings — Investor Presentation (October 2026) on 6ix